On 12 December 2018, the General Court (“Court”) partially annulled the European Commission’s decision of 9 July 2014 in the Servier case and consequently reduced Servier’s fine by more than 30%, from €330.99 million to...more
12/21/2018
/ Abuse of Dominance ,
Annulment ,
Anti-Competitive ,
Antitrust Violations ,
EU ,
European Commission ,
European Patent Office ,
Fee Reductions ,
General Court of the European Union (GCEU) ,
Generic Drugs ,
IP License ,
Patent Validity ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Reverse Payment Settlement Agreements ,
Settlement Agreements ,
Treaty on the Functioning of the European Union (TFEU)
The UK Competition and Markets Authority (“CMA”) recently published its infringement decision of 7 December 2016 that imposed a fine on Pfizer and Flynn Pharma (“Flynn”) for abusing their respective dominant positions by...more
9/22/2017
/ Abuse of Dominance ,
Antitrust Investigations ,
Appeals ,
Cancer ,
Drug Pricing ,
Excessive Pricing ,
Fines ,
Infringement ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
National Health Service Corp (NHSC) ,
Pfizer ,
Pharmaceutical Industry ,
Prescription Drugs ,
UK ,
UK Competition and Markets Authority (CMA)
The Court of Justice of the European Union (CJEU) has quashed a ruling by the EU’s General Court which had upheld the European Commission’s (EC) 2009 finding of abuse of dominance by Intel Corporation Inc. Intel was fined...more
9/8/2017
/ Abuse of Dominance ,
Anti-Competitive ,
Appeals ,
Competition ,
Court of Justice of the European Union (CJEU) ,
Customer-Loyalty Programs ,
European Commission ,
Intel ,
Jurisdiction ,
Manufacturers ,
OEM ,
Pricing ,
Rebates ,
Set-Asides ,
Standard of Review ,
Treaty on the Functioning of the European Union (TFEU)